Zacks Research Decreases Earnings Estimates for Haemonetics

Haemonetics Co. (NYSE:HAE - Free Report) - Analysts at Zacks Research decreased their Q1 2026 earnings per share estimates for shares of Haemonetics in a report issued on Thursday, June 5th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $1.01 per share for the quarter, down from their prior forecast of $1.03. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q2 2026 earnings at $1.16 EPS, FY2026 earnings at $4.84 EPS, Q2 2027 earnings at $1.31 EPS, FY2027 earnings at $5.41 EPS and FY2028 earnings at $6.02 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period last year, the company earned $0.90 earnings per share. Haemonetics's revenue was down 3.5% on a year-over-year basis.

Several other research firms have also issued reports on HAE. Raymond James reiterated a "strong-buy" rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. Finally, Needham & Company LLC cut their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Trading Up 0.4%

Shares of NYSE HAE opened at $70.71 on Monday. The firm has a market cap of $3.40 billion, a PE ratio of 27.84, a price-to-earnings-growth ratio of 1.11 and a beta of 0.36. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics has a twelve month low of $55.30 and a twelve month high of $94.99. The business has a fifty day simple moving average of $64.06 and a two-hundred day simple moving average of $69.48.

Institutional Investors Weigh In On Haemonetics

Several large investors have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics in the 4th quarter valued at $25,000. Quarry LP raised its holdings in shares of Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after buying an additional 192 shares during the last quarter. Covestor Ltd raised its stake in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after acquiring an additional 439 shares during the last quarter. Whittier Trust Co. acquired a new stake in shares of Haemonetics during the fourth quarter worth $62,000. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in Haemonetics in the 1st quarter valued at approximately $65,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.